Audited Results and cash dividend declaration for the year ended 30 June 2025 -- 1 of 62 -- 2 Performance overview Normalised profit +29% to R15 210m New business1 -2% to R26 486m Headline earnings +30% to R9 625m Normalised headline earnings +30% to R9 781m 1 Excluding discontinued products Non-insurance income +12% to R6 643m excl. Sasolmed +8% -- 2 of 62 -- 3 Key insights Excellent start to the FY25-FY29 growth corridor 1 2 3 Robust FY25 operating performance across the Group Clarity of strategy and growth through two business composites Acceleration of trends underpinning the relevance of the Group’s Vitality Shared-value model and unique data 4 -- 3 of 62 -- 4 FY25 performance -- 4 of 62 -- 5 Strong profit performance Health 4 259 +7% Life1 5 525 +14% Invest 1 987 +29% Insure 817 +229% Bank -68 -85% Other SA2 -515 +91% SA 12 005 +22% Vitality Health 1 188 +173% Vitality Life 637 +70% Vitality Network 554 +4% Ping An Health Insurance 1 206 +7% VHI - Other -291 -25% Other Vitality -89 -54% Vitality (UK and VG) 3 205 +70% Normalised profit, ZARm 1 Includes Umbrella Funds 2 Vitality and Group initiatives and central costs to R15 210m +29% Strong normalised profit growth +22% +70% FY25 profit growth: FY25 -- 5 of 62 -- 6 Supportive below-the-line performance R million Actual Actual % 2025 2024 Normalised profit from operations 15 210 11 761 29% Forex gains/(losses) -36 -87 1 DP finance lease impact -72 -105 Finance charges excl. 1DP finance lease -1 810 -1 750 Investment income and fair value gains on financial instruments 457 480 Other -254 -131 Profit before tax 13 495 10 168 33% Taxation1 -3 937 -2 619 Profit after tax 9 558 7 549 27% Profit not attributable to ordinary shareholders -231 -209 Loss on derecognition of intangible assets 112 35 Impairment- Held for sale 79 - Impairment of intangible assets 55 6 Other headline earnings adjustments 52 3 Headline earnings 9 625 7 384 30% Amortisation of intangibles from business combinations 104 90 Restructuring costs 61 37 Other normalised headline earnings adjustment -9 - Normalised headline earnings 9 781 7 511 30% 1 The effective tax rate in the prior year was c.2% lower than the current rate as a result of a deferred tax asset raised on losses in the individual policyholder fund Final dividend declared 201 cps Full-year dividend 288 cps, 33% growth 5x dividend cover -- 6 of 62 -- 7 Robust cash generation lifts cash conversion ratio Cash conversion ratio is calculated as Operating Cash Flow (R8 997m at 30 June 2025, from the ‘Additional Analyst Information’ document) over the IFRS normalised profit/(loss) from operations (R15 822m at 30 June 2025, from section A.1 Segment Information of the ‘Audited Results’) net of IFRS income tax expense (R4 089m at 30 June 2025, from section A.1 Segment Information of the ‘Audited Results’) Adjusted Net Cash Flow (Rbn) Before ordinary dividends, capital movements and one-offs New business and tax Operating Cash Flow R17.7bn Cash generated from in-force R9.0bn Cash generated 76.7% cash conversion ratio Cash uses before capital movements and dividends Net Cash Flow excl. capital movements and dividends Net Cash Flow Capital movements and dividends R5.4bn R1.6bn -R1.7bn Dividends -R1.6bn Debt capital movements Financing and matching activities R3.6bn -R1.9bn Investment in growth Discovery Health Discovery Life Discovery Invest Vitality Health Vitality Life Insure -R6.8bn New business net of external funding -R1.9bn Tax -R1.7bn Finance costs -1.01 0.90 2.10 5.45 FY22 FY23 FY24 FY25 R3.8bn -R0.5bn -- 7 of 62 -- 8 Robust growth in Group Embedded Value (EV) 15.7% Return on EV ▪ Non-economic experience variances contributed positively to the Group EV, offsetting a strengthening to the basis ▪ Non-covered businesses: Positive contributions from PAHI and Insure, in line with profit, and the break-even of the Bank, further supported growth ▪ Additional uplift from economic impacts, including forex movements Opening EV Value of new business Unwind of risk discount rate Non-economic experience variances and methodology & assumption changes Operational EV Economic experience variances and methodology & assumption changes Non-covered businesses Forex Finance costs, investment income & other Change in captial & dividends Closing EV R124 994m R110 354m R126 554m -- 8 of 62 -- 9 Focus on quality new business Health1 9 573 +12% 1 343 +7% Life 3 203 -10% Individual Life 2 733 -2% Group Life and UF 470 -41% Invest 3 430 +4% Insure 1 361 -2% Bank 2 338 +29% Vitality 546 +33% SA1 18 113 +5% 3 681 +20% Vitality Health 2 851 +3% Vitality Life 2 499 +28% Vitality Network 1 977 +4% Ping An Health Insurance 3 023 +22% VHI - Other 985 +5% Other Vitality Vitality (UK and VG) 8 373 +16% 2 962 +5% Total excl. Sasolmed 26bn +8% 7bn +12% Total 26bn -2% 7bn +12% New business Non-insurance income ZARm 1 Excl. Sasolmed +8% New business Excl. Sasolmed in prior period 0 5 000 10 000 15 000 20 000 25 000 30 000 FY01 FY02 FY03 FY04 FY05 FY06 FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 Sasolmed FY25 to R26 486m -- 9 of 62 -- 10 Strong client growth Vitality lives includes customers in the UK, and lives covered globally including free AIA members and corporates SA Vitality excl. PAHI PAHI 0 5 10 15 20 25 30 35 2021 2022 2023 2024 2025 Millions to 6.4m +6% to 10.4m +25% to 32.1m +17% 0 1 2 3 4 5 6 7 2021 2022 2023 2024 2025 Millions 0 2 4 6 8 10 12 2021 2022 2023 2024 2025 Millions -- 10 of 62 -- 11 FY25-FY29 growth corridor -- 11 of 62 -- 12 Discovery businesses have been built organically Group operating profit CPI + 10% Previous Organic Growth Model ESTABLISHED EMERGING NEW ~3 years ~5 years Profit growth of CPI + 5% Profit growth of CPI + 30% Growth in investment of CPI + 10% 90% 20% -10% of profit of profit of profit -- 12 of 62 -- 13 0% 10% 20% 30% 0 2 4 6 0% 20% 40% 60% 80% 0% 5% 10% 15% 20% 25% 0% 10% 20% 30% -20% -10% 0% 10% 20% 30% 40% The result is different phases of growth % spend on new Dividend cover Cash conversion ratio (normalised history) Normalised profit growth FLR Normalised RoE Scaled organic growth 15-20% RoE 15-20% CAGR c5% Spend on new 10-20% FLR ≤5x Dividend cover 60-70% Cash conversion ratio Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors and reflects the average expected over the time frame Illustrative ranges Big investments in New Unfettered organic growth Average 13% Average 20% Average 22% Average 3% 4.6x 5.7x CAGR IFRS 4 9% CAGR 22% 8% 15% 56% 60% Average Average Average Average Average Average FY 2006 FY 2007 FY 2008 FY 2009 FY 2010 FY 2011 FY 2012 FY 2013 FY 2014 FY 2015 FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2026 FY 2027 FY 2028 FY 2029 FY 2025 -- 13 of 62 -- 14 Strong delivery in the first year of the five-year growth corridor Strong normalised profit growth IFRS 17 0 2 000 4 000 6 000 8 000 10 000 12 000 14 000 16 000 FY01 FY02 FY03 FY04 FY05 FY06 FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 14% 15-yr CAGR 0% 5% 10% 15% 20% 25% 30% SA excl bank Bank Vitality Total FY25 cumulative profit growth contribution 29% 17% + 5% + 8% Target corridor of growth Outperformance in FY25 -- 14 of 62 -- 15 On track to achieve five-year CAGR ambition Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors and reflects the average expected over the time frame Strong performance in the first year of delivery has increased confidence in achieving this ambition over the period % spend on new Dividend cover Cash conversion ratio Normalised profit growth FLR Normalised RoE Guidance 15-20% RoE 15-20% CAGR c5% Spend on new 10-20% FLR ≤5x Dividend cover 60-70% Cash conversion ratio 15.4% FY25 16.8% FY25 29% FY25 3% FY25 76.7% FY25 FY25 5x FY25 Operating profit corridor (Applying CAGR target to FY24 profit) 15% 20% - 5 000 10 000 15 000 20 000 25 000 30 000 35 000 FY20 FY21 FY22 FY23 FY24 FY25 FY29 -- 15 of 62 -- 16 Group is financially strong 1 Normalised for COVID-19 reserve impact, refer to Annexure A; 2 Capital Adequacy Ratio; 3 Comprehensive Solvency Ratio, definition set by China Banking and Insurance Regulatory Commission Improving cash conversion Strongly capitalised FLR decreasing Group cash conversion ratio1 Financial leverage ratio Solvency cover DHMS solvency (unaudited) Jun 24 Cover Jun 25 Cover Life 1.8x 1.9x Insure 1.6x 2.1x VH 1.6x 1.8x VL 2.0x 2.0x Bank2 1.3x 1.2x PAHI3 3.2x 3.3x 76.7% 30% 40% 50% 60% 70% 80% FY21 FY22 FY23 FY24 FY25 10% 15% 20% 25% FY22 FY23 FY24 FY25 16.8% 31.7% -- 16 of 62 -- 17 Capital allocation framework Strategic choices Normalised profit growth Cash conversion ratio Normalised RoE Leverage % spend on new Dividend cover 15-20% CAGR FY25-FY29 60-70%FY25-FY29 15-20% FY25-FY29 ≤5x FY25-FY29 c5%FY25-FY29 10-20% FY25-FY29 Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors and reflects the average expected over the time frame -- 17 of 62 -- 18 Strong growth platforms -- 18 of 62 -- 19 Acceleration of disruptive environmental trends Nature of risk Technology Social responsibility Demographic • Risk due to modifiable behaviours: 37% of healthcare expenses are due to modifiable behaviours • Causality of behaviour change: mortality, sickness and healthcare costs are significantly impacted by behaviour change. This impact is universal; it holds across age, gender, and health status; and is elastic - so even more significant for people who are older and sicker Nature of risk Demographic Technology Social responsibility • Ageing populations impact on healthcare: there is a corresponding rise in the incidence of chronic diseases as populations age, leading to a surge in healthcare expenses. Ageing demographics also contribute to a growing demand for long-term care services, further straining financial resources • Heightened obesity levels: obesity rates are increasing and the impact on healthcare costs is substantial • AI and machine learning advances: Agentic AI is emerging as a transformative force, with autonomous systems reshaping industries, workforces, and competitive dynamic • Benefits and costs of drug innovations: The rise of GLP-1 treatments is altering consumer behaviour, and softening demand in the food and beverage sector • Stakeholder needs are more widely defined: businesses face pressure to create value for all stakeholders through their products, services and client journeys • Evolution of value-based care: accelerated pressure on stakeholders to improve quality of care and decrease costs, through a patient-centric approach of global deaths due to NCDs ~75% Mortality risk from no to high exercise (45-65 yrs) -58% Requires a deep understanding of risk and how to manage it Requires preventative interventions and disease management programmes to improve population health Requires sophisticated analytics to deliver hyper- personalised solutions Requires a shared-value business model of the population will be 60+ by 2030 25-35% Per person retirement gap in the US (2023) $60k Potential medical cost savings by year 10 due to GLP-1s ~$18bn AI infrastructure planned spend by US tech firms in 2025 ~$400bn of traditional Medicare patients in an accountable care relationship with a provider 53.4% global sustainable AUM $3.5tr -- 19 of 62 -- 20 Rich multi-market dataset that integrates behavioural and operational data Claims Screenings Device Demographics Incentive partner preferences Telematics Lifestyle (sleep + nutrition) Underwrriting Pathology & radiology Vitality Money Workflow processing App & Web logs Virtual agent & live chat Sales agent data Transactions/ payments Marketing comms System logs Transaction data >100 AI models and initiatives developed, leveraging advanced AI techniques and tools >150 internal data pipelines integrating data into big data environments, with built-in privacy protections >72 individual databases housing structured data across the business >1.4 petabytes Structured data (health, wellness, and mortality) & unstructured data (images, emails, and voice recordings >25 years of historical structured & unstructured data captured and retained OPERATIONAL DATA BEHAVIOURAL DATA Pricing & benefit optimisation Behaviour assessment & risk prediction Behavioural coaching Operational efficiency -- 20 of 62 -- 21 Data is structured in a way that enables cross-domain insights linking behaviour and risk Absolute impact of REM sleep on insure AvE of damage frequency REM sleep has a significant impact on driving risk across all statuses Relative impact of REM sleep on insure AvE of damage frequency Example: Understanding the link between REM sleep and risk of car accidents 140% 120% 100% 80% 60% 0% 40% 20% Blue Bronze Silver Gold Diamond Vitality drive status AvE Accident damage frequency ±15% absolute impact across all statuses from lower REM sleep >1-hour avg REM <1-hour avg REM 1.3x 1.25x 1.2x 1.15x 1.10x 1.05x Blue Bronze Silver Gold Diamond Vitality drive status AvE Accident damage frequency 120% -> 105% = 1.14 130% -> 115% = 1.12 110% ->95% = 1.15 90% -> 75% = 1.20 75% -> 60% = 1.25 -- 21 of 62 -- 22 This has enabled the evolution of the Vitality Shared-value Insurance model driven by hyper-personalisation Proprietary data Dynamic risk assessment Vitality.AI recommender Incentivised engagement Insurance integration -- 22 of 62 -- 23 +22% +70% FY25 profit growth: -- 23 of 62 -- 24 Discovery SA Discovery Bank Discovery Insure Discovery Invest Discovery Life Discovery Health Discovery Corporate Employee Benefits reported as a division of Discovery Life -- 24 of 62 -- 25 Strong focus and ambition for Discovery South Africa 1 Retail affluent market share 2 Excluding white labelled funds 1 2 3 Ensuring each business is a market leader in terms of market share, margin, product innovation and enhanced customer value Scale Discovery Bank with an ambition to achieve 2m clients and R3bn in profits in FY29 # 1 fastest growing short-term insurer by GWP 3rd largest in net flows2 # 1 market share # 1 market share1 Each product sits on the Bank, with a consistent architecture, and the Bank Operating System as the single interface for the Discovery SA Composite -- 25 of 62 -- 26 Discovery Bank Deposits Normalised profit Revenue (NII+NIR) +30% +26% -85% +31% to 1.2m to R23.3bn to (R68m) to R2.4bn Advances +39% to R9.2bn Total accounts Total clients +32% to 3.0m NII includes the allocation of interest earned on the bond trading portfolio (recognised at fair value gains in the income statement) 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 NII NIR 2021 2022 2023 2024 2025 Profitable in H2 H1 2020 H2 2020 H1 2021 H2 2021 H1 2022 H2 2022 H1 2023 H2 2023 H1 2024 H2 2024 H1 2025 H2 2025 Accounts Clients H1 -- 26 of 62 -- 27 0% 1% 2% 3% 4% 5% 6% Credit card Homeloans Dec-24 Jun-25 Quality lending with engaged clients Monthly advances by product (Rm) 1 Market average source: Annual Financial statements of the top 5 SA banks per product category, 2 % top of wallet refers to the proportion of clients that are estimated use Discovery Bank as their primary bank account for spending, based on breadth of spend, value of spend relative to income, and type of spend. Rebased to SCF or transaction only Advances CLR Engagement Homeloans >R2bn balance as at 8 Sep-25 Credit loss ratio by product* Jul-21 Oct-21 Jan-22 Apr-22 Jul-22 Oct-22 Jan-23 Apr-23 Jul-23 Oct-23 Jan-24 Apr-24 Jul-24 Oct-24 Jan-25 Apr-25 Credit Card Advances DTA Overdrafts Access Facility Lending Home loans Personal Loans Revolving Credit Facility launched Homeloans launched Personal loans launched Relative % top of wallet by product suite Market average (Dec-24) 0% 100% 200% 300% 400% 500% 600% 700% 800% 900% SCF or Transaction only SCF / Transaction + RCF SCF/ Transaction + HL/PL SCF/Transaction + RCF + HL/PL Transaction Single Credit Facility Overdrafts Revolving credit facility -- 27 of 62 -- 28 NII and NIR cohort analysis NII PCPM by months on book NIR PCPM by months on book Profit PCPM by months on book Based on internal analysis and excludes Not Good Standing; Indexed to month 0 of 2023-01 cohort 2023-01 cohort 2025-06 cohort 0 5 10 15 20 25 30 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 0 5 10 15 20 25 30 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 0 5 10 15 20 25 30 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 -- 28 of 62 -- 29 A full-service, digital shared value retail Bank Fastest growing1 retail Bank in South Africa with market-leading digital capabilities Four key hypotheses Full retail banking product suite1 | Shared-value banking model2 | Digital-first with advanced AI capabilities3 | Operating system of the composite4 | 1 Using organic balance sheet growth; The analysis considers year-on-year growth, retail deposits: adjusting for the impact of any mergers or acquisitions, retail advances: credit cards (excl. overdrafts) and home loans. It does not consider other factors such as profitability, customer experience and operational scale. Based on June 2025 BA900s -- 29 of 62 -- 30 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2015 2017 2019 2021 2023 2025 Non-scheme products Restricted schemes DHMS 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 Discovery Health 1 Sasolmed contributed R2 510m to new business for FY2024 2 Reported number of lives under administration is not a unique count Normalised profit New business Non-scheme growth Membership +7% -14% 3.98m to R4 259m to R9 573m Lives under administration2 >448k lives +18% Sasolmed1 closed scheme Jan-18 Aug-18 Mar-19 Oct-19 May-20 Dec-20 Jul-21 Feb-22 Sep-22 Apr-23 Nov-23 Jun-24 Jan-25 Flexicare Gap cover Healthy Company AHI Jun -25 (Excl. Sasolmed) +12% VHIA -- 30 of 62 -- 31 0% 1% 2% 3% 2021 2022 2023 2024 2025 Upgrades Downgrades 0% 5% 10% 15% 20% 25% 30% 35% 40% 0 5 10 15 20 25 30 35 2021 2022 2023 2024 2025 Reserve Actual solvency Required solvency Discovery Health Medical Scheme (DHMS): continued excellent performance in a complex environment Membership and open market share as at June 2024 Plan changes exclude impact of plan closures Membership Customer satisfaction Solvency 58.0% market share Low proportions of members change plans, with more members upgrading than downgrading: Lapses continue to remain stable R32.2bn 31.7% AAA projected unaudited reserves projected unaudited solvency credit rating R billion 95% no plan changes DHMS Rest of the industry Others 0% 2% 4% 6% 8% 10% 2021 2022 2023 2024 2025 -- 31 of 62 -- 32 Personal Health Pathways (PHPs) drives positive behavioural change while delivering positive impact for DHMS PHP activation and engagement statistics as at 4 September 2025 Personal Health Fund (PHF); Next Best Action (NBA) 361k activated lives Member activation and engagement Driving behaviour change through incentivisation 3% 11% 3% 3% 16% 56% 52% 25% 17% 9% 19% 52% 2024 2025 Online NBAs Visit your practitioner Cancer & other screenings* Vaccines Diagnostic tests Collect your medicine 27 NBAs in 6 categories 383% increase in the completion rate from 2024 to 2025 5.2x increase in total number of completed actions 357k Health actions completed 1.95m Exercise actions completed R27.2m rewards earned R197m PHF funds earned 69% of all health and exercise actions completed are from chronic members Chronic *Include screenings for: Colon cancer, Mammogram, Pap/HPV, Foot (podiatrist), DR, Prostate cancer -- 32 of 62 -- 33 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2025 2025 2021 2022 2023 2024 2025 Discovery Life Normalised profit Cash generation Capital and liquidity +14% to R5 525m (Individual Life) SCR coverage Total liquidity 192% 2 675m 1X ILT 125% SCR Target -10% to R3 203m Market share source: NMG market report Q2 2025 Discovery Life Ltd New business Maintained 27% market share of the underwritten retail risk business 3,3 Covid impact -0,7 1,5 2,2 -0,2 +52% Discovery Life Ltd Cash flow before financing initiatives and dividends to Group (Rbn) +11% (Individual Life) -2% Discovery Life includes Individual Life and Corporate & Employee Benefits IFRS 17 -- 33 of 62 -- 34 Premium, fees & investment income Cashflow before financing/ funding to Group Robust claims performance driving strong cash generation Excellent claims experience validating the shared value model Strong cash generation in Life and Invest driven by favourable claims and market growth Mortality experience by Vitality status relative to expected (AvE) None Blue Bronze Silver Gold Diamond Financing repayment Dividend to Group Cash outflows R3.3bn R23.4bn -R12.1bn Claims -R4.4bn Operational costs -R3.6bn New business cash conversion ratio ~60% (Rbn) R1.6bn R1bn Jul 2020 – Jun 2025 Long-term expected FY25 -78% 100% -- 34 of 62 -- 35 June 2024 New Business Expected Unwind excl. new business Experience Variances Basis changes Dividends Other June 2025 45 948 461 4 663 1 129 737 - 988 214 52 164 June 2024 Assumption changes Indiv Life volumes Group Life volumes Other June 2025 Positive operating variances and robust EV growth with VNB margin impacted by lower volumes Growth in Embedded Value VNB margin impacted by lower NB volumes 3.8% Individual Life: 5.0% (20.0% IRR) 2.1% Life (excl. Invest) VNB margin (%) Individual Life: 3.8% (18.5% IRR) 15.7% Annualised RoEV* *Before dividend payments. 13.2% excl. economic updates Mortality and morbidity Persistency Premium and fee income Policy alterations Other Total non-economic Economic Total Discovery Life Ltd EV variances (Rm) R841m R1 129m Positive operating variances Discovery Life Ltd EV growth (Rm) Persistency Premium & fee income Other Total non -economic Economic Total Policy alterations* Mortality & morbidity *Defined action plan being phased in to address policy alterations June 2024 June 2025 June 2025 June 2024 -- 35 of 62 -- 36 Discovery Invest Source: Ninety One; Net flows excluding reinvestments, Money Market and FOF. Including both retail and institutional flows Normalised profit Assets under administration Net flows New business +29% +15% 14% +4% to R1 987m to R179bn Since 2015 to R3 430m 2021 2022 2023 2024 2025 API from guaranteed Discovery Invest Other asset managers +9% Excl. guaranteed 2021 2022 2023 2024 2025 Once-off items +15% Excl. one-offs Jan-18 Sep-18 May-19 Jan-20 Sep-20 May-21 Jan-22 Sep-22 May-23 Jan-24 Sep-24 May-25 One off items IFRS 17 -- 36 of 62 -- 37 Well positioned to grow in the current context Introducing private market investments to Discovery clients Risk Return Efficient frontier including public and private markets Efficient frontier including public markets Cogence Diversified Markets Portfolio Cogence Global Diversified Markets Portfolio 15% private market exposure 15% private market exposure Cogence in partnership with BlackRock >R28bn assets under management 65 68 71 74 77 80 83 86 89 92 95 Leveraging actuarial dynamics to combine shared value with longevity protection Guaranteed income from age 80 Income boosts of up to 50% >90% more cost effective than a traditional fixed annuity -- 37 of 62 -- 38 Discovery Insure Solvency Normalised profit Insurance revenue +229% +8% to R817m to R6 217m 212% -2% to R1 361m Gross new business 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 IFRS 17 -- 38 of 62 -- 39 Recovery driven by deliberate structural improvements Improved loss ratio from management actions across the value chain Upfront selection Persistency Claims Profitability New business book based on insurance risk exposure Quality of the new business book has strengthened 75% 80% 85% 90% 95% 100% 2019 2020 2021 2022 2023 2024 2025 Superior risk profile Average risk profile -0.4% -1.2% -0.4% -0.5% -1.3% -1.4% -2.0% -0.9% -2.5% Claims initiatives Other external factors FY24 loss ratio FY25 loss ratio Expected weather improve- ment Upfront selection Under- writing actions Pricing actions Selective lapsation uplift Unexpected weather improve- ment Duration uplift FY25 loss ratio before non- recurring factors -- 39 of 62 -- 40 Discovery SA Proprietary data Dynamic risk assessment Vitality.AI recommender Incentivised engagement Insurance integration Discovery Bank Discovery Insure Discovery Invest Discovery Life Discovery Health -- 40 of 62 -- 41 Vitality Vitality Health International Vitality Network Vitality UK -- 41 of 62 -- 42 Considerable work done to restructure the business to unlock efficiencies, globalise capabilities and deliver growth Announcement of a single global business, Vitality Phase 1: Exploration Aug – Oct 2024 Phase 2: High-level operating model Nov 2024 – Feb 2025 Phase 3: Growth strategies and efficiencies Mar – Jun 2025 Phase 4a: Regionalisation Phase 4b: Vitality AI Jul 2025 onwards Efficiencies through rolling off contractors and removing duplicate roles Clearly identified growth opportunities Created the Vitality Distribution Academy to support sales Established Global IP hubs to harness best practice Unified our approach to development, design and delivery of technology assets underpinned by Vitality AI Regionalisation Deliver Vitality AI -- 42 of 62 -- 43 USA NETWORK UK -- 43 of 62 -- 44 Vitality UK Operating profit Premium income Lives covered New business +126% +15% +7% +14% to £77.7m to £1.3bn to 2.0m to £228m 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2m lives IFRS 17 -- 44 of 62 -- 45 Vitality UK’s differentiated brand is a powerful asset Brand awareness at all-time high, surpassing competitors UK at the centre of building a global brand H2 2014 H1 2015 H2 2015 H2 2015 H1 2016 H1 2017 No… H1 2019 H2 2019 H1 2020 H2 2020 Early H2 2021 H2 2021 H1 2022 No… H1 2023 H2 2023 H1 2024 H1 2025 Competitor Average Vitality +357% Growth since 20141 1 H1 2025 Vitality Brand Survey, Immerse UK 64 63 Reviewed and verified to meet the requirements of the UK Code of Broadcast Advertising Peer reviewed by LSE by engaging with the Vitality Programme Up to 5 years longer Elevated brand messaging that highlights shared value Iconic core brand assets New global tagline Unique brand campaigns Stanley No measure No measure Vitality Pink Roundel -- 45 of 62 -- 46 VitalityHealth Normalised profit Premium income1 New business Lives covered +174% +16% +3% +3% to £50.6m to £814.5m to £121.4m to 1.1m IFRS 17 1 Insurance revenue 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 -- 46 of 62 -- 47 Pricing actions and stabilising claims experience have restored margins 1. Premiums rebased successfully to claims experience 2. Robust and selective retention Premiums vs claims PLPM (3-month average, rebased to Jul-23) Operating margin vs earned premiums 0% 2% 4% 6% 8% 10% 12% 14% 2018 2019 2020 2021 2022 2023 2024 2025 2026 (plan) Margin (actual) Margin (plan) 7.5% margin COVID-19 impact 3. Margin recovery combined with revenue growth c.15% Renewal lapse rate lower than plan (FY 2025) Expected margin (FY 2026) 7.5% Lapse rates and claims relativity by Vitality status Bronze Silver Gold Platinum Individual SME Claims relativity Overall lapse rate Bronze Silver Gold Platinum SME Individual Claims relativity 90% 95% 100% 105% 110% 115% 120% 125% 130% Jun-23 Dec-23 Jun-24 Dec-24 Jun-25 Premium PLPMs Claims PLPMs (rolling 3m) Claims and premium PLPMS back in line -- 47 of 62 -- 48 VitalityLife Normalised profit Premium income Lives covered New business IFRS 17 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 +70% +11% +28% +12% to £27.1m to £447.8m to £106.4m to 904k lives -- 48 of 62 -- 49 New business API (£’m) Momentum in new business performance has continued, driven by Vitality Shared-value Insurance Step change in new business Increased footprint to unlock future growth Establishing solid market share 1.GenRe Protection Pulse 2.Swiss Re Term & Health Watch 2025 Report. 3rd in ‘New Term APE (with and without CI)’, ‘New IP policies’, ‘New CI APE’ in 2024 calendar year. 83.1 106.4 FY24 FY25 +28% Advisers writing (rolling 3 months) VitalityLife market share1 Jun 24 Jul 24 Aug 24 Sep 24 Oct 24 Nov 24 Dec 24 Jan 25 Feb 25 Mar 25 Apr 25 May 25 Jun 25 +30% 7.4% 8.4% 10.4% 10.9% 13.5% FY21 FY22 FY23 FY24 FY25 3rd largest market share2 3 425 2 703 -- 49 of 62 -- 50 Growth is focused on writing quality new business with no compromise to new business profitability VL quote competitiveness on portals Competing selectively – priced at a premium and not buying share Benefiting from scale and expense efficiencies Net change in margins (CSM and RA) Drivers of new business value (rebased to FY24 H1) New business net value (£m) (CSM and RA, less onerous new business) . Resulting in significant change in new business value generated FY24 H1 FY24 H2 FY25 H1 FY25 H2 Sales Underlying profitability Per policy initial expenses1 1. VL's premium relative to average of cheapest 5 providers on a quote (an indicator of premium competitiveness) 2. Underlying profitability defined as the % of PV of premiums available to cover initial expenses and profit. FY25 shown before basis changes for consistency with the previous periods Optimiser premium lowest for 54% of quotes 16.1 46.9 7.1 53.9 FY24 FY25 Reported net value Basis Change 52.1 8.9 9.1 13.3 39.0 New Business Interest Accretion VIF Monetisation Release to Earnings Basis change 109% 95% 6% 54% Standard Optimiser Compete ratio1 Lowest premium +73% -28% 100% Compete ratio1 Underlying profitability2 Per policy initial expenses Change in margin (£m) (CSM and RA) . -- 50 of 62 -- 51 NETWORK -- 51 of 62 -- 52 Vitality Network Integrated API by insurance partners +24% to $1 951m Normalised profit +7% to $30.5m 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 Revenue +8% to $109m 2021 2022 2023 2024 2025 Insurance partners membership +27% to 6.7m 2021 2022 2023 2024 2025 -- 52 of 62 -- 53 Positive impact of shared value observed across markets Blue Bronze Silver Gold Diamond Relative claims rates 57% lower Relative lapse rates 53% lower Blue Bronze Silver Gold Diamond The Shared-value model is creating value for both John Hancock Vitality customers and John Hancock of Vitality members with high blood pressure or high cholesterol readings are now in-range 50% 45% of Vitality members reported a reduction in BMI of Vitality members reported similar or better health YoY 80% of John Hancock customers use Vitality 66% Reduction in lapse rates for Vitality Plus members on higher status levels relative to Non-Vitality Plus members 60% 2019 2024 6% increase in proportion of off-Blue members Member engagement Relative claims rates 39% lower Relative lapse rates 48% lower Consistent member engagement Member engagement Relative claims rates 70% lower Relative lapse rates 63% lower 2019 2025 61% Member engagement % of members earned a point Member engagement Bronze Silver Gold Platinum Bronze Silver Gold Platinum 2019 2024 Blue Bronze Silver Gold Blue Bronze Silver Gold 4th largest life insurance market 3rd largest life insurance market 1st largest life insurance market -- 53 of 62 -- 54 Positioning the business for future scale and growth 1 Restructuring of existing partnerships Launching the next evolution of Vitality products through Vitality AI Rapid pursuit of new opportunities across Europe and North America 2 3 Opportunity to establish optimal, long- term partnerships in Europe, following the Generali partnership termination Vitality AI launch in November 2025 Leveraging Vitality AI to drive engagement Enhancing Shared-value outcomes by investing back into the AIA Vitality partnership, alongside AIA Collectively committed to 5m lives by 2030, with restructured economics to simplify and capture the emergence of value Termination of the partnership due to strategic misalignments Leveraging the launch of Vitality AI to drive growth in North America -- 54 of 62 -- 55 Vitality AI is the future of behavioural insurance in a hyper-personalised world *Underwritten by the global reinsurance market – with a panel of the big six reinsurers participating Proprietary Data Dynamic Risk Assessment Vitality.AI Recommender Incentivised Engagement Insurance Integration Wedge funding Dynamic pricing Vitality Product Reinsurer panel* World-class technology platform Vitality engagement toolkit Vitality Global Partner and Rewards Network Personalised communication Habit laddering & gamification >60m Life years of behavioural linked insurance data Global data engineering Habit index Propensity model Reward elasticity model Next best action model Device- led Causal inference model Value model HealthyFutures algorithm -- 55 of 62 -- 56 Case study of the value to a life insurer and life insurance member driven by the shared-value model Initial internal modelling based on a European insurer Value to the insurer Value to the member Case study based on initial internal modelling of a Term Life portfolio with European market dynamics. Range provides an indication of value based on underlying market dynamics and engagement with Vitaliy, with engagement ranging between 20 – 40% Member value derived from their Vitality term life policy over the lifetime of the policy. Case study based on a 40-year-old male who purchases an indexed term life policy with a 20-year term and £500k sum assured Relative VNB margin uplift Case study: lifetime member uplift Bronze Silver Gold Platinum -1.3 to 11.5 times year 1 premium Non-optimised Term Life Shared-value actuarial benefits: Improved lapses, claims and reinsurance premiums Value shared with member: Through insurance integration structure Shared-value commercial benefits: Additional growth and better business mix Total value 48 – 79% increase in value -- 56 of 62 -- 57 2021 2022 2023 2024 2025 Investment income and gains Profit before investment income and gains Ping An Health Insurance PAHI’s operating results pre-tax Discovery’s operating result after tax PAHI licence new business1 PAHI licence earned premium1 +22% +10% +25% +21% to RMB2.5bn (RMB636m DSY’s share) to RMB479m to RMB4.8bn to RMB17.8bn Lives +17% to 32.1m PAHI licence lives 1 100% of PAHI 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 Tax benefit DSY Profit After Costs +8% before investment income and 2024 COVID release -- 57 of 62 -- 58 0 2 4 6 8 10 12 14 2021 2022 2023 2024 2025 Strong market fundamentals continue to support high quality, sustainable earnings Continued growth in market share PAHI market share (%) 2 6.3% 7.0% 7.7% 8.1% 9.6% 2021 2022 2023 2024 2025 Superior operational margin Net profit margin 3 -4% -2% 0% 2% 4% 6% 8% 10% 12% 2019 2020 2021 2022 2023 2024 Balance sheet strength enabling dividends RMB 699 million PAHI cash dividend: (ZAR 1.8 billion)4 Private health sector well positioned for growth Solvency (RMB billion) and Comprehensive SCR (%) Commercial health insurance share of innovative drug coverage (%) 1 44% 44% 7% 44% 49% 12% 2025 2035 Out of Pocket Commercial Health Insurance Basic Medical Insurance Supportive government systematic medical and health reforms 334% 320% 267% 231% 277% 2. PAHI's market share of accessible sectors of the market 1. ChinaRe Report (2025) 3. Note: In transition phase to IFRS-17, there are discrepancies between the accounting standards 4. 100% PAHI gross of withholdings tax. Assumes spot rate as at dividend declaration -- 58 of 62 -- 59 Vitality Proprietary data Dynamic risk assessment Vitality.AI recommender Incentivised engagement Insurance integration Partner Markets North America Europe Asia UK -- 59 of 62 -- 60 Summary Excellent start to the five-year growth corridor 1 2 3 Robust FY25 performance Clarity of strategy and growth through two business composites Increasing relevance of the Group’s Vitality Shared-value model 4 12.5% to 17.5% average earnings growth p.a. (FY25-FY29) 20% to 30% average earnings growth p.a. (FY25-FY29) Normalised profit growth 15-20% CAGR FY25-FY29 Normalised profit +29% to R15 210m New business1 -2% to R26 486m Headline earnings +30% to R9 625m Normalised headline earnings +30% to R9 781m Non-insurance income +12% to R6 643m excl. Sasolmed +8% -- 60 of 62 -- 61 Presentation disclaimer This presentation may contain forward looking statements with respect to certain of Discovery’s plans and its current goals and expectations relating to its future performance and results. All forward looking statements involve risk and uncertainty because they relate to future events and circumstances which are beyond Discovery’s control. Accordingly, Discovery’s actual future financial performance and results may differ. Any reference to future financial performance has not been reviewed or reported on by the Group’s auditors. -- 61 of 62 -- Audited Results and cash dividend declaration for the year ended 30 June 2025 -- 62 of 62 --